Form 4: Astera Labs CEO Sells $20.7M in Shares via 10b5-1 Plan

Astera Labs CEO Jitendra Mohan sold 157,500 common shares for approximately $20.7 million through a pre-arranged 10b5-1 trading plan.

Summary

• Jitendra Mohan, the Chief Executive Officer and a Director of Astera Labs, Inc. (ALAB), executed sales of 157,500 shares of the company's common stock.
• The transactions occurred on March 17, 2026, and were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025.
• The shares were sold at weighted average prices ranging from $125.5575 to $134.6738 per share, with the overall sale value estimated at approximately $20.7 million.
• Following these sales, Mohan's indirect beneficial ownership through a living trust decreased from 4,680,478 shares to 4,531,732 shares.
• Mohan continues to hold 1,452,739 shares directly and maintains indirect beneficial ownership through several other estate planning trusts, including a Trust (699,999 shares), 2021 Trust 1 (700,000 shares), 2021 Trust 2 (700,000 shares), 2022 Trust 1 (450,001 shares), and 2022 Trust 2 (450,001 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns of opportunistic trading, indicating a planned liquidity event rather than a reaction to new information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions and reducing concerns about opportunistic insider selling based on non-public information.

Negatives

• A significant sale of 157,500 shares by the CEO, even if planned, could be interpreted by some investors as a reduction in personal exposure to the company's stock.

Risks

• NA

Future Outlook

NA

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that pre-scheduled insider sales via Rule 10b5-1 plans are a common practice among executives for personal financial planning, diversification, and liquidity, and do not necessarily reflect a change in management's outlook on the company's future performance. Such plans are designed to allow insiders to sell shares without concerns of trading on material non-public information.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Sales of common stock by the Chief Executive Officer, Jitendra Mohan, who is a related party.
• Shares are held indirectly through various estate planning trusts (Living Trust, Trust, 2021 Trust 1, 2021 Trust 2, 2022 Trust 1, 2022 Trust 2) of which the Reporting Person is a trustee or beneficiary, representing related party holdings.

Stakeholder Impact

• Shareholders may observe a reduction in the CEO's direct equity stake, which could be interpreted as a signal, although the pre-planned nature of the sales under a 10b5-1 plan typically lessens negative implications.

Next Steps

• NA

Key Dates

Recommendation

The sales by the CEO were executed under a pre-arranged 10b5-1 trading plan, which is a routine financial planning activity for executives. This type of transaction typically does not signal a change in the company's fundamentals or future prospects, thus a 'hold' recommendation is appropriate as it does not provide new information to alter an investment thesis.

Keywords

Astera Labs, ALAB, Jitendra Mohan, CEO, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, Common Stock